Genzyme Corp. to Pay $22.28 Million to Resolve False Claims Allegations Related to "Slurry" Used in Patients
Genzyme Corp. has agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a "slurry" version of its Seprafilm adhesion barrier, the Justice Department announced today. Seprafilm is a thin film intended to reduce adhesions after surgery by forming a bio-resorbable barrier between abdominal tissue and organs. Genzyme is a biotechnology corporation based in Cambridge, Mass., and was acquired by Sanofi-Aventis SA in April 2011.
- Date:December 20, 2013
- Agency:U.S. Department of Justice
- Criminal and Civil Actions